Georges Rawadi holds a PhD in microbiology from the University of Paris VI (Pierre et Marie Curie) and trained in business administration and management at ESSEC Business School. Forover 25 years, he has held various positions in the pharmaceutical/biotechnology industry as a scientist, drug discovery professional, business development expert and as an executive and entrepreneur supporting biotech companies in their pipeline and financing strategy. Georges is currently a board member of several biotech companies and was CEO of Celyad Oncology and YSOPIA Bioscience. Previously, he was Head of Biotech Studio Development at EureKare and Vice President of Business Development and Intellectual Property, as well as a member of Celyad Oncology's management team. Prior to this, he successfully held various management positions in business development at Cellectis, Galapagos, ProStrakan and Sanofi-Aventis, and led consulting assignments in the development of strategic alliances.

Ana Hennino is at the origin of the project, she completed her PhD as an ENS student in Immunology at the INSERM in Lyon in 2001. She developed during PhD studies expertise in molecular mechanisms involved in apoptosis in B cell compartment and identified c-FLIP as a key regulator of the apoptosis of B cells in the germinal center.

Through her post-doctoral studies in the field of immunology of allergy she demonstrated an important role of the CD8+ T cell response at the initiation of the skin-allergic immune response. Since 2014, her research in CancerResearch Center Lyon focuses on the regulation of the immune response by the stromal compartment in the context of autoimmunity and cancer.

Karine holds a MSc in Biochemistry and she has worked for 18 years in the field of biotechnology. Her career started in2006 at Idealp Pharma, expert in drug discovery, developing scientific skills in cell culture and large screening of compounds to select good lead for neurological application. For 14 years, she led at Erytech Pharma therapeutic projects dedicated to oncology at several positions as engineer, project manager and project director. Through her career, Karine built strong expertise in PK/PD,POC in different model systems, Mechanism of action and safety to support clinical phases and regulatory needs. She coordinated R&D program and team implementing laboratory and management practices, the CMC support and the cross functional link with clinical and regulatory strategies moving from phase 1 to phase 3 clinical trials (IB, ATMP, IMPD, IND, CTA).

Eric is an expert in early clinical development and helps Stromacare to fine tune its clinical pathway. He is head of medical oncology at Groupe Hospitalier Paris Saint-Joseph since 2016.

He spent all his carrier in oncology department of prestigious hospitals : Lausanne Hospital, Beaujon Paris Hospital, Saint-Louis Paris Hospital, IGR Paris. He is MD and holds a PhD in Molecular Biology from Pierre et Marie Curie Paris University.

José has spent the last 25 years in biotech companies working, among others, as Director of Quality Assurance, Director of Nonclinical studies, and Director of Clinical studies. He has also led a project up to Phase 3 clinical trial.

He has a broad experience in biological drugs development, from biomanufacturing to clinical trial operations. In its last position, he has set up and managed the Quality Management System for both internal research activities and for GxP subcontracted activities that has allowed to release more than 10 different Investigational Medicinal Products for clinical trials (Phase 1 to Phase 3).

‍

Alex has worked on various academic preclinical R&D projects in the fields of oncology, immunology and virology in France and Canada. He has acquired expertise in assay development for the screening, functional characterization, and batch release of therapeutic molecules, particularly for humanized monoclonal antibodies.

For the past 6 years, he has worked in the Netherlands as a senior immuno-oncology scientist in a clinical-stage biotechnology company developing innovative bispecific antibodies to treat, and potentially cure patients with diverse forms of cancer.